CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 129 enrolled
Drug / intervention
FX006 32 mgdrug
Likely dose
FX006 32 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03529942
NCT03529942Phase 3Completed
CompareCT.gov

An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients With Osteoarthritis of the Knee

Pacira Pharmaceuticals, Inc·interventional·Posted May 18, 2018·Updated Jan 24, 2024

In Brief

A Phase 3 clinical trial evaluating FX006 32 mg for Osteoarthritis, Knee. Completed, enrolled 129 participants across 10 sites in 2 countries.

Detailed Summary

This is an open-label study assessing the effect of the administration of a single intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with osteoarthritis (OA) of the knee.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesUnited Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 18, 2018
Enrollment StartApr 24, 2018
Primary CompletionNov 8, 2019
Study CompletionMar 9, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.1 years ago

Interventions

FX006 32 mgdrug

Extended-release 32 mg FX006 IA injection